Anticoagulant therapy after retinal vein occlusion in patients with protein S deficiency [2]

Canadian Journal of Ophthalmology

Volumn 42, Issue 6, 2007, Pages 875-

  Rehak, Matus ^a,b   Krcova, Vera ^a   Slavik, Ludek ^a   Müller, Marc ^b   Rebak, Jiri ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; PROTEIN S; WARFARIN;

ANTICOAGULANT THERAPY; DISEASE ASSOCIATION; GENE MUTATION; GERIATRIC PATIENT; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; LETTER; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN S DEFICIENCY; RETINA VEIN OCCLUSION; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 38149119653     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i07-175     Document Type: Letter

References (3)

1. Sucak GT, Aki Z, Or M. Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. Can J Ophthalmol 2007;42:632-3.
2. Goodwin A, Rosendaal F, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002;126:1349-66.
3. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for cenrral retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:507-19, 524.